小于4 cm实性肾肿块的MRI生长模式能否用于预测良性组织学
单中心回顾性评估63例肾细胞癌与36例良性肿块(13例乏脂肪血管平滑肌脂肪瘤、23例嗜酸细胞瘤)的T2加权MRI生长模式,发现良性肿块外生性生长百分比更大(p<0.001),而角界面征和气泡征无鉴别价值。
要点
- 良性肿块(乏脂肪血管平滑肌脂肪瘤和嗜酸细胞瘤)的外生性生长百分比大于肾细胞癌。
- 90%–100%外生性生长仅见于良性肿块,肾细胞癌中未见。
- 角界面征和气泡征不能用于鉴别良性肿块与肾细胞癌。
核心结论
- 良性肿块显示更大的外生性生长百分比,其他生长模式无鉴别价值;未来需用多变量MR分析评估外生性生长百分比。
研究设计与样本
- 单中心经IRB批准的研究,纳入63例肾细胞癌(透明细胞22例、乳头状28例、嫌色细胞13例)和36例良性肿块(乏脂肪血管平滑肌脂肪瘤13例、嗜酸细胞瘤23例),由两名盲法放射科医师独立评估T2加权MRI,采用ANOVA、卡方检验和多变量回归进行比较。
关键影像表现/征象
- 角界面征在肾细胞癌中阳性率为11.1%(7/63)至9.5%(6/63)(R1/R2),在良性肿块中为13.9%(5/36)至19.4%(7/36)(R1/R2)(p=0.68和0.16)。
- 气泡征在肾细胞癌中阳性率为11.1%(7/63)至3.2%(2/63)(R1/R2),在良性肿块中为16.7%(6/36)至8.3%(3/36)(R1/R2)(p=0.432和0.261)。
- 乏脂肪血管平滑肌脂肪瘤外生性生长百分比为66±32%(范围0–100%),嗜酸细胞瘤为53±26%(范围0–90%),均大于肾细胞癌的32±23%(范围0–80%)(p<0.001)。
- 90%–100%外生性生长见于38.5%(5/13)的乏脂肪血管平滑肌脂肪瘤和17.4%(4/23)的嗜酸细胞瘤,肾细胞癌中未见。
- 长轴与短轴比值在组间无差异(p=0.053)。
诊断标准与关键数值
- 外生性生长百分比为连续变量,良性组(乏脂肪血管平滑肌脂肪瘤66±32%,嗜酸细胞瘤53±26%)高于肾细胞癌组(32±23%),p<0.001。
- 90%–100%外生性生长仅见于良性肿块:乏脂肪血管平滑肌脂肪瘤38.5%(5/13),嗜酸细胞瘤17.4%(4/23),肾细胞癌0例。
- 角界面征鉴别良恶性无统计学意义(p=0.68和0.16)。
- 气泡征鉴别良恶性无统计学意义(p=0.432和0.261)。
临床应用与阅片要点
- 在实性肾肿块阅片时,可观察外生性生长百分比,良性肿块倾向于更高比例,但原文未给出具体诊断阈值。
- 90%–100%外生性生长仅见于乏脂肪血管平滑肌脂肪瘤和嗜酸细胞瘤,肾细胞癌中未见。
- 角界面征和气泡征对鉴别良性肿块与肾细胞癌无帮助。
- 两名医师对角界面征和气泡征的主观评估一致性为中等(K=0.50和0.55)。
局限性
- 原文结论指出未来需用多变量MR分析评估肾肿块的外生性生长百分比。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To evaluate previously described growth patterns in < 4 cm solid renal masses.
MATERIALS AND METHODS: With IRB approval, 63 renal cell carcinomas (RCC; clear cell n = 22, papillary n = 28, chromophobe n = 13) and 36 benign masses [minimal-fat (mf) angiomyolipoma (AML) n = 13, oncocytoma n = 23) from a single institution were independently evaluated by two blinded radiologists (R1/R2) using T2-weighted MRI for (1) the angular interface sign (AIS), (2) bubble-over sign (BOS), (3) percentage (%) exophytic growth and (4) long-to-short axis ratio. Comparisons were performed using ANOVA, chi-square and multi-variate regression.
RESULTS: AIS was present in 11.1% (7/63) -9.5% (6/63) R1/R2 RCC compared to 13.9% (5/36) -19.4% (7/36) R1/R2 benign masses (p = 0.68 and 0.16). BOS was present in 11.1% (7/63) -3.2% (2/63) R1/R2 RCC compared to 16.7% (6/36) -8.3% (3/36) R1/R2 benign masses (p = 0.432 and 0.261). Agreement was moderate (K = 0.50 and 0.55). mf-AML [66 ± 32% (range 0-100%)] and oncocytoma [53 ± 26% (0-90%)] had larger % exophytic growth compared to RCC [32 ± 23% (0-80%)] (p < 0.001). No RCC had 90-100% exophytic growth, present in 38.5% (5/13) mf-AMLs and 17.4% (4/23) oncocytomas. The long-to-short axis did not differ between groups (p = 0.053).
CONCLUSIONS: Benign masses show greater % exophytic growth whereas other growth patterns are not useful. Future studies evaluating % exophytic growth using multi-variate MR analysis in renal masses are required.
KEY POINTS: • Greater exophytic growth is associated with benignity among solid renal masses. • Only minimal fat AMLs and oncocytomas had 90-100% exophytic growth. • The angular interface sign was not useful to differentiate benign masses from RCC. • The bubble-over sign was not useful to differentiate benign masses from RCC. • Subjective analysis of growth patterns had fair-to-moderate agreement.
引用
- Lim RS, McInnes MDF, Siddaiah M, et al. Are growth patterns on MRI in small (< 4 cm) solid renal masses useful for predicting benign histology? Eur Radiol. 2018. PMID: 29492598. doi:10.1007/s00330-018-5324-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。